Universitätsklinikum Essen

Prediction of Complete Remission and Survival in Acute Myeloid Leukemia Using Supervised Machine Learning (2021) Eckardt JN, Rollig C, Kramer M, Stasik S, Georgi JA, Heisig P, Kroschinsky FP, et al. Conference contribution Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute BLymphoblastic Leukemia (INITIAL-1 trial) (2021) Stelljes M, Alakel N, Waesch R, Scholl S, Nachtkamp K, Rank A, Haenel M, et al. Conference contribution Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography (2021) Oprea-Lager DE, Cysouw MC, Boellaard R, Deroose CM, de Geus-Oei LF, Lopci E, Bidaut L, et al. Journal article, Review article Quantification of translocation-specific ctDNA provides an integrating parameter for early assessment of treatment response and risk stratification in ewing sarcoma (2021) Krumbholz M, Eiblwieser J, Ranft A, Zierk J, Schmidkonz C, Stuetz AM, Peneder P, et al. Journal article German S1 guideline: diagnosis and treatment of livedovasculopathy (2021) Schiffmann ML, Dissemond J, Erfurt-Berge C, Hafner J, Itzlinger-Monshi BA, Jungkunz HW, Kahle B, et al. Journal article S1-Leitlinie Diagnostik und Therapie der Livedovaskulopathie (2021) Schiffmann ML, Dissemond J, Erfurt-Berge C, Hafner J, Itzlinger-Monshi BA, Jungkunz HW, Kahle B, et al. Journal article Tumor Immunology The new fourth Pillar of Tumor Treatment (2021) Kasper S, Rammensee HG, Gaipl U, Hoeffken K Journal article, Editorial Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF(V600) mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial (2021) Zimmer L, Livingstone E, Krackhardt A, Schultz ES, Goppner D, Assaf C, Trebing D, et al. Journal article Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis (2021) Zaremba A, Kramer R, De Temple V, Bertram S, Salzmann M, Gesierich A, Reinhardt L, et al. Journal article Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia (2021) Rautenberg C, Stoelzel F, Roellig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, et al. Journal article